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ABSTRACT
Purpose: In uveal melanoma, specific chromosomal
abnormalities are known to correlate with the risk of
metastases; changes in chromosomes 3 and 8q correlate
strongly with a decreased survival of the patient, whereas
chromosome 6 abnormalities are associated with a better
prognosis. Usually, karyotyping and fluorescence in situ
hybridization (FISH) analysis are used to detect these
abnormalities in resected tumor tissues. However, the
evaluation of these chromosomal changes is compromised
in patients treated with eye-retaining treatment protocols
because of the lack of tumor material. The purpose of this
study was to validate the use of FISH for the analysis of
genetic prognostic markers.
Experimental design: We analyzed 40 uveal melanoma
fine needle aspiration biopsies (FNABs) and the correspond-
ing main tumor with FISH.
Results: All biopsies were found to contain tumor cells,
and FISH analyses of the samples were successful in all
cases. Statistical analysis showed very good agreement be-
tween the FISH results from the biopsies and those from the
main tumor. In only 2 of 249 hybridizations did we find a
small variation that could have led to a misclassification.
Conclusions: Our results indicate that the application of
FISH to FNABs is a reliable method for assaying genetic
prognostic parameters such as chromosome 3 loss and/or
chromosome 8q gain. Implementation of this method in a
diagnostic setting means that we are able to identify patients
at risk of developing metastatic disease, not only in enucle-
ated patients but also in cases treated with conservative
treatment modalities such as radiotherapy.
INTRODUCTION
Uveal melanoma is the most common primary intraocular
tumor with an annual incidence of 0.7/100,000 in the Western
population (1). Although 2% of the patients have clinically
detectable metastases at presentation, 50% of all patients
ultimately die of metastatic disease. The median survival after
the diagnosis of metastasis is extremely poor. No effective
treatment exists for metastatic disease, but new approaches for
the management of metastases, involving IFN, interleukin, and
a combined chemo- and immunotherapy are under study (2, 3).
The predictive value of classic histological prognostic pa-
rameters such as tumor size, vascular patterns, and histological
cell type has been analyzed in several retrospective studies.
Additional clinical parameters associated with a poorer progno-
sis are extrascleral growth, tumor location (ciliary body), older
age, and male gender (4). Prescher et al. (5) showed that loss of
chromosome 3, in comparison with tumor location or tumor
diameter, is a better prognostic parameter of relapse-free and
overall survival. Sisley et al. (6) confirmed the prognostic value
of monosomy 3 and, in addition, demonstrated a strong inverse
correlation between the presence of additional copies of 8q and
survival. In contrast, patients with tumors having chromosome 6
abnormalities appear to have a better prognosis (7).
Although enucleation is still indicated in large uveal mel-
anoma, radiotherapy (such as proton beam irradiation or plaque
therapy, with or without transpupillary thermotherapy) has be-
come the first choice of treatment for patients with small- or
medium-sized melanomas (8). A clear advantage for the patient
is saving the eye and vision, but the lack of histological speci-
mens compromises the evaluation of the prognostic markers.
Because FNABs have been used successfully for several years
for intraocular tumor diagnosis (9, 10), the analysis of FNABs2
offers an attractive and safe alternative in these cases.
In the present study, we have investigated the possibility of
applying FISH analysis to FNABs. FNABs were obtained ex
vivo, i.e., after enucleation of the tumor-containing eye, and
directly used for FISH analyses. To investigate whether these
FNAB samples are a good representation of the main tumor,
larger samples of the main tumor were processed for direct
FISH analysis and conventional cytogenetics. The results of the
FNAB were compared with those of the main tumor.
MATERIALS AND METHODS
Patients and Tumor Samples. From January 1997 to
December 1999, we collected FNABs and matched tumor ma-
terial from 40 uveal melanoma patients. These patients were
referred for enucleation of the affected eye to the Department of
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Ophthalmology, University Hospital Rotterdam and the Rotter-
dam Eye Hospital. Informed consent was given before enucle-
ation, and the study was performed according to the tenets of the
Declaration of Helsinki. The mean age was 60.5 years (range,
34–85); 19 patients were male, and 21 were female. The mean
tumor diameter was 12.9 mm (range, 7–18 mm). Five tumors
were derived from the ciliary body and 35 from the choroid.
Immediately after enucleation, transvitreal FNABs were taken,
and both the FNABs and fresh tumor material were processed
for FISH and/or cytogenetic analysis according to standard
procedures. Histopathological diagnosis and treatment of the
patient were not compromised by biopsy collection. Cytogenetic
studies were carried out on peripheral blood samples of each of
the patients to exclude the presence of congenital balanced
chromosome abnormalities.
FNABs. After enucleation, the bulbus was first transillu-
minated to define the location of the tumor. A 25-gauge needle
attached to a 10-ml syringe was inserted through the sclera into
the tumor, and suction was applied to the syringe. After sam-
pling, the pressure was equalized before removal of the needle
to avoid seeding of tumor cells. Cells were collected in culture
medium, fixed in methanol:acetic acid, and FISH preparations
were made as described (11).
Fresh Tumor Material. Tumor specimens, collected af-
ter ex vivo FNABs, were processed as described (12). For direct
FISH, 1 ml of the cell suspension was fixed, and the remaining
Fig. 1 Results of the FISH studies carried
out on 40 FNABs of uveal melanoma and
the corresponding tumor.
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cell suspension of the tumor was cultured. For cytogenetic
analysis, cells were incubated with Colcemid (0.15 g/ml) for
6 h at 37°C and fixed. The chromosome preparations were
stained with acridine orange or atebrine to obtain R or Q
banding. Cytogenetic abnormalities were described in accord-
ance with the International System for Human Cytogenetic
Nomenclature (Basel, 1995). Remaining cultures were stored in
N2 and in one instance (EOM-121) used for additional FISH
studies. FISH analysis on metaphases using locus-specific
probes, and whole chromosome painting was carried out to
further characterize the abnormalities in cases where cytoge-
netic analyses revealed the presence of partially defined chro-
mosomes.
FISH. Dual color FISH was performed using centro-
meric and locus-specific cosmid, P1, or YAC probes for chro-
mosomes 3 and 8. Probes for chromosomes 1 and 6 were used
if sufficient material was available. FISH was performed using
standard procedures (11). The concentration for centromeric
probes was 5 ng/slide; for cosmids, P1, and YAC probes, 50–75
ng/slide were used. The probes used were p1–79 (1p36), P 3.5
(centromere 3), YAC 827D3 (3q24), cos85 (6p21), and cos52
(6q23) (Prof. Y. Nakamura, Tokyo, Japan), Cos105H8 (8p11),
D8Z2 (centromere 8), and ETO (8q22). After hybridization and
washing, slides were counterstained with 4,6-diamidino-2-
phenylindole and mounted in anti-fade solution (Dabco-
Vectashield 1:1). Signals were counted in 300 interphase nuclei
according to the criteria of Hopman et al. (13). Cutoff limits for
chromosome loss (15% of the nuclei with one signal) or gain
(10% of the nuclei with three or more signals) were adapted
from the available literature (14). Variation found by FISH (in
FNAB and the main tumor) were subdivided into five categories
(Fig. 1): loss of one copy, normal copy numbers (two copies),
gain of one copy, gain of two copies, and gain of more than two
copies. When different subclones were identified, only the FISH
findings of the largest clone were used to classify the material.
Statistical Analysis. To evaluate the agreement between
the FISH results obtained from the FNAB and those obtained
from the direct preparations of the tumor, we calculated the
overall kappa, as well as the kappa of all probes separately.
Kappa 0.20 was considered as a poor strength of agreement,
0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as good,
and 0.81–1.00 as very good. The Wilcoxon’s matched pairs
signed rank sum test was used to compare the number of FISH
Table 1 Cytogenetic analysis of the main tumor



































EOM-182a 46,XX,der(6)t(6;6)(q16;p12), der(22)t(8;22)(?;p11), der(22)t(6;22)(?;q13)[16]
EOM-187 45,X,Y,3,4,i(8)(q10),i(8)(q10),mar[1]
EOM-189 44,XY,1,2,3,dic(1;6)(q10;q10),ring[5]/45,idem,8,[12]/90,XXYY,idem, 8, 8[1]
a In these cases, conventional cytogenetics were supplemented with spectral karyotyping (15).
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probes successfully used on the FNAB samples with the number
of probes used on the direct preparation.
RESULTS
Fig. 1 shows the results of the FISH analyses performed on
40 FNAB specimens taken from enucleated eyes of uveal mel-
anoma patients and the corresponding primary tumors. The
findings of the conventional karyotype studies on the primary
tumors are given in Table 1. Examples of karyotype analysis and
FISH of patient EOM-121 are shown in Fig. 2. In this case, no
direct preparations could be made because of shortage of ma-
terial, and a short-term culture (passage 1) was used for FISH
and karyotype analysis of the main tumor.
FISH Results on the FNABs versus Direct Preparations
of the Main Tumor. All FNABs yielded sufficient tumor
cells to allow FISH analysis. The number of probes used in the
FISH analysis on the FNABs was not significantly different
from the number of probes used on the direct tumor preparations
(Wilcoxon’s matched pairs signed rank sum test, P 	 0.197). In
eight instances, all eight probes could be tested on the FNAB
and the main tumor. In 39 of 40 FNABs, the FISH of both
chromosomes 3 and 8 could be analyzed. In one case (EOM-
138), the FNAB was of low quality, and as a result, only
chromosome regions 1p36 and 3q24 could be analyzed.
In 11 of 249 hybridizations, discrepancies between the
FISH results of the FNAB and those of the corresponding tumor
were detected (summarized in Table 2). In three instances [re-
gions 8p11/8q22 (EOM-151), 8q22 (EOM-157)], this variation
was because of classification of the largest clone only (three
versus four copies of chromosome 8). In one tumor (EOM-171),
FISH results of the FNAB suggested an additional chromosome
8 (gain of all chromosome 8 probes), whereas the tumor sug-
gested the formation of an isochromosome 8q (normal chromo-
some 8p11, gain of centromere 8, and gain of two copies of
chromosome 8q22). Thus, in both cases, gain of chromosome 8q
was observed. In 6 of 249 hybridizations, FISH showed normal
copy numbers in the FNAB but abnormal numbers in the tumor
samples. In five of these six hybridizations [EOM-148 (centro-
mere 8), EOM-150 (6q23), EOM-151 (3q24), and EOM-178
(8p11/8q22)], this concerned small abnormal subclones (12–
17% of nuclei) that were detected in the main tumor, whereas
they remained undetected in the FNAB. In EOM-138, a sub-
clone of 32% of nuclei showing gain of chromosome region
1p36 in the main tumor was not found when analyzing the
FNAB. To investigate the agreement between the FISH results
of the FNAB and those of the direct tumor preparation, we
calculated the weighted kappa of all probes separately and an
overall weighted kappa. The overall weighted kappa was 0.95
(range for the probes separately, 0.90–1.00), indicating a very
good agreement between the FISH results obtained from
FNABs and those obtained from the main tumor.
FISH Results versus Cytogenetic Analysis of Main Tu-
mor. Cytogenetic analysis of the melanomas could be per-
formed in 26 of 40 cases. We found variation between the FISH
findings of the FNABs and main tumors and those expected
from the cytogenetic analysis. In most instances (EOM-130,
EOM-147, EOM-159, EOM-165, EOM-177, EOM-178, and
EOM-182), the variation was attributable to the presence of
partially defined or complex cytogenetic abnormalities and
could be resolved by applying metaphase FISH using whole
chromosome paints or spectral karyotyping (15). In other cases
(EOM-123, EOM-157, and EOM-158), normal karyotypes were
found after culturing, whereas FISH revealed abnormalities. In
two cases (EOM-174 and EOM-187), only one metaphase could
be analyzed because of poor tumor growth in vitro, and in 5
other cases (EOM-148, EOM-150, EOM-151, EOM-152, and
EOM-160), minor variations were found between the cytoge-
netic and FISH results. In EOM-125, the FISH analyses re-
vealed two copies for the chromosome 1p36 and centromere 3
probes. However, cytogenetic studies showed a triploid karyo-
type with only two copies of chromosome region 1p36 and
disomy for chromosome 3. This indicates a relative loss of these
chromosome regions in this tumor, although the FISH had
shown no abnormalities.
DISCUSSION
In this study, we describe the application of FISH for
determining of the presence of genetic abnormalities in FNABs
Fig. 2 A, karyotype of patient EOM-121: 47 XY,del(1)(p31p36),3,
der(4)t(1;4)(q12;q21),8,21. B, nuclei isolated from short-term cul-
ture of the tumor specimen hybridized with chromosome 3q24 (green)
and 1p36 (red) probes. C, nuclei isolated from FNABs hybridized with
probes for centromere 3 (green) and centromere 8 (red).
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of uveal melanoma. The results of our study indicate that the
tumor cells obtained by the FNAB are representative of the main
tumor, and that the chromosomal aberrations detected by FISH
in these FNAB specimens are concordant with the major clonal
genetic changes observed by conventional cytogenetics or FISH
analysis of the main tumor.
In 249 of 293 hybridizations, we investigated both FNAB
and the matched tumor, and statistically, we found a very good
agreement between the FISH results of the FNAB and those of
the main tumor. Variation between these results was observed
for individual probes in 11 hybridizations, a total of 7 cases.
However, because more than one probe had been used for the
identification of each chromosome, in six of these tumors
[EOM-148, EOM-150, EOM-151 (chromosome 8), EOM-157,
EOM-171, and EOM-178], the presence of prognostically sig-
nificant genetic variation could still be established. The results
in 2 of 249 hybridizations (0.8%) would have led to the mis-
classification of the tumor. In EOM-138, we observed only a
gain of chromosome region 1p36 in 32% of the main tumor cells
and not in the FNAB. Gain of chromosome 1 is a very rare
finding in uveal melanoma, and the prognostic relevance of this
abnormality is unknown. In EOM-151, only the main tumor
showed a subclone with loss of chromosome region 3q24,
whereas the centromeric probe for chromosome 3 showed nor-
mal copy numbers in both tumor and FNAB samples. In one
case, the use of a reference probe or DNA ploidy, e.g., centro-
meric probes for chromosomes 2, 12, or 13; chromosomes,
which are rarely involved in numerical abnormalities in uveal
melanoma; or a combined approach of karyotype and FISH
analysis could have been helpful to identify the relative loss of
chromosomes 1p36 and 3 in a tumor with a hypertriploid karyo-
type (EOM-125).
The differences between FISH and cytogenetic analysis
can be explained by culture artifacts, because the overgrowth of
normal cells is not rare when culturing tumor cells. Addition-
ally, FISH has an increased level of resolution for the detection
of genetic abnormalities that may not be visible by conventional
chromosome studies.
Sisley et al. (16) recently demonstrated, using cytogenetic
techniques, that all major clonal alterations were detectable in
both FNABs and the main tumor. They showed that with short-
time cultures of FNABs, conventional cytogenetic analysis was
possible in 60% of the cases. The advantage of FISH for
identifying genetic variation, as we have demonstrated in the
present study, is that it is easier to perform, and the risk of
selecting particular cell populations during culture is avoided.
Folberg et al. (17) found only a modest correlation (r 	
0.57) between the SD of the nucleolar area measured in FNABs
and that measured in the matched enucleation sample and con-
cluded that the FNABs were unsuitable for determining prog-
nosis using these parameters. However, the differences in sam-
ple size between tumor (200 cells/sample) and FNAB (50 cells/
sample) in their study could explain their results.
One must keep in mind that these FNABs were performed
ex vivo under ideal circumstances on relatively large tumors, and
we were able to use up to eight probes to compare the FISH
results of the FNAB with those of the matched tumor. When
these biopsies are taken under less favorable i.e., in vivo con-
ditions on tumors planned to be treated with radiation therapy,
FISH analysis using probes for chromosome 3 and 8 will be
sufficient to predict the outcome of the patient because it is
generally accepted that variations of these chromosomes are of
high prognostic significance. Furthermore, we3 and others have
shown that these biopsies can also be performed in smaller
lesions suspected for uveal melanoma (10), enabling this
method to be used in patients preferentially treated with radio-
therapy. Our study justifies further studies using in vivo biopsies
which could enable us to investigate the use of chromosome
analysis on FNABs even more accurately.
Until now, no specific regions or genes on chromosomes 3
and 8 involved in the tumorigenesis of uveal melanoma have
been identified. However, from our comparative genomic hy-
bridization and spectral karyotyping study, we do have indica-
tions that region 8q21.1–21.2/q23–24 and 3q13–21 may be
3 Unpublished results.
Table 2 FISH results of cases with discrepancies between FNAB and tumora
Tumor Locus Materialb
Copy number detected by FISH (% in FNAB/ tumor)c
1 2 3 4 4
EOM-138 1p36 F/T 2/0 88/61 1/6 8/32 1/1
EOM-148 cen8 F/T 0/2 90/83 2/12 8/3 0/0
EOM-150 6q23 F/T 4/17 91/77 3/6 2/0 0/0
EOM-151 3q24 F/T 5/16 79/83 10/1 6/0 0/0
8p11 F/T 0/0 22/8 41/15 36/77 1/0
8q22 F/T 0/0 23/6 35/10 29/65 13/19
EOM-157 8q22 F/T 0/0 59/60 15/25 26/15 0/0
EOM-171 8p11 F/T 0/0 8/96 91/3 1/1 0/0
8q22 F/T 0/0 7/2 89/13 4/84 0/1
EOM-178 8p11 F/T 2/0 98/87 0/12 0/1 0/0
8q22 F/T 0/0 96/83 4/15 0/2 0/0
a Only cases in which differences in chromosome copy numbers were observed between FNAB and corresponding tumor are indicated in this
table.
b F, FNAB; T, tumor.
c Percentage of cells in FNAB/tumor showing 1, 2, 3, 4, or 4 FISH signals, respectively, for the investigated chromosome locus.
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involved (15). Should these regions prove to be the target
regions, more specific FISH probes can be designed to improve
the predictive outcome of this technique.
Our results demonstrate clearly that FISH analysis of
FNAB specimens can be used to examine for the presence of
specific chromosomal abnormalities in the tumor cells of uveal
melanoma patients. This method is particularly suitable in cases
where no tumor tissue has been resected and/or when patients
are treated with eye-retaining treatment protocols such as irra-
diation or radioactive plaque therapy. Detection of these abnor-
malities provides important additional information for predict-
ing the outcome of these patients and will help to recognize
those individuals particularly at risk of developing metastatic
disease. The earlier detection of metastases and, if available, the
introduction of appropriate adjuvant therapies during primary
treatment could contribute to a better survival rate of uveal
melanoma patients.
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